234 related articles for article (PubMed ID: 26933761)
21. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
22. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
Soares DG; Escargueil AE; Poindessous V; Sarasin A; de Gramont A; Bonatto D; Henriques JA; Larsen AK
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13062-7. PubMed ID: 17656556
[TBL] [Abstract][Full Text] [Related]
23. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
Guirouilh-Barbat J; Zhang YW; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):1985-94. PubMed ID: 19584235
[TBL] [Abstract][Full Text] [Related]
24. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
[TBL] [Abstract][Full Text] [Related]
25. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair.
Lu H; Guo X; Meng X; Liu J; Allen C; Wray J; Nickoloff JA; Shen Z
Mol Cell Biol; 2005 Mar; 25(5):1949-57. PubMed ID: 15713648
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
27. ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity.
Fujinaka Y; Matsuoka K; Iimori M; Tuul M; Sakasai R; Yoshinaga K; Saeki H; Morita M; Kakeji Y; Gillespie DA; Yamamoto K; Takata M; Kitao H; Maehara Y
DNA Repair (Amst); 2012 Mar; 11(3):247-58. PubMed ID: 22188649
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
29. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
30. Dynamics of chromosomal aberrations, induction of apoptosis, BRCA2 degradation and sensitization to radiation by hyperthermia.
Bergs JW; Oei AL; Ten Cate R; Rodermond HM; Stalpers LJ; Barendsen GW; Franken NA
Int J Mol Med; 2016 Jul; 38(1):243-50. PubMed ID: 27246457
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
32. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
33. The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair.
Yue J; Wang Q; Lu H; Brenneman M; Fan F; Shen Z
Cancer Res; 2009 Oct; 69(20):7978-85. PubMed ID: 19808958
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
35. Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation in a time- and temperature-dependent manner.
Genet SC; Fujii Y; Maeda J; Kaneko M; Genet MD; Miyagawa K; Kato TA
J Cell Physiol; 2013 Jul; 228(7):1473-81. PubMed ID: 23254360
[TBL] [Abstract][Full Text] [Related]
36. Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.
van den Tempel N; Odijk H; van Holthe N; Naipal K; Raams A; Eppink B; van Gent DC; Hardillo J; Verduijn GM; Drooger JC; van Rhoon GC; Smedts DHPM; van Doorn HC; Boormans JL; Jager A; Franckena M; Kanaar R
Int J Hyperthermia; 2018 Jun; 34(4):407-414. PubMed ID: 28705099
[TBL] [Abstract][Full Text] [Related]
37. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Moneo V; Serelde BG; Fominaya J; Leal JF; Blanco-Aparicio C; Romero L; Sánchez-Beato M; Cigudosa JC; Tercero JC; Piris MA; Jimeno J; Carnero A
J Cell Biochem; 2007 Feb; 100(2):339-48. PubMed ID: 16888811
[TBL] [Abstract][Full Text] [Related]
38. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
39. Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.
Quiros S; Roos WP; Kaina B
PLoS One; 2011; 6(11):e27183. PubMed ID: 22073281
[TBL] [Abstract][Full Text] [Related]
40. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
